Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature

被引：9

作者：

Karaca, Halit ^{[1
]}

Lale, Ayhan ^{[2
]}

Dikilitas, Mustafa ^{[1
]}

Ozkan, Metin ^{[1
]}

Er, Ozlem ^{[1
]}

机构：

[1] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey

[2] Erciyes Univ, Dept Internal Med, Fac Med, Kayseri, Turkey

来源：

MEDICAL ONCOLOGY | 2010年 / 27卷 / 03期

关键词：

Renal cell carcinoma; Paraneoplastic hypercalcemia; Sunitinib; TYROSINE KINASE INHIBITOR; GROWTH-FACTOR; SU11248; CANCER; INTERFERON; SURVIVAL;

D O I：

10.1007/s12032-009-9327-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor. It has higher response rates and progression-free survival in patients with metastatic renal cell carcinoma (RCC) when compared with standard chemotherapy and interferon-a. We report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33-years-old man with metastatic RCC. At the sixth month of follow-up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life-threatening entity.

引用

页码：1023 / 1026

页数：4

共 27 条

[11] Hypercalcemia in the emergency department [J].

Lee, CT ;

Yang, CC ;

Lam, KK ;

Kung, CT ;

Tsai, CJ ;

Chen, HC .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2006, 331 (03) :119-123

[12]

Mendel DB, 2003, CLIN CANCER RES, V9, P327

[13]

Motzer RJ, 2006, J CLIN ONCOL, V24, p930S

[14] Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma [J].

Motzer, RJ ;

Bacik, J ;

Schwartz, LH ;

Reuter, V ;

Russo, P ;

Marion, S ;

Mazumdar, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :454-463

[15] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

[16]

MUNDY GR, 1984, NEW ENGL J MED, V310, P1718

[17] SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model [J].

Murray, LJ ;

Abrams, TJ ;

Long, KR ;

Ngai, TJ ;

Olson, LM ;

Hong, WR ;

Keast, PK ;

Brassard, JA ;

O'Farrell, AM ;

Cherrington, JM ;

Pryer, NK .

CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (08) :757-766

[18]

Newman Elan M, 2006, Endocr Pract, V12, P535

[19] SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo [J].

O'Farrell, AM ;

Abrams, TJ ;

Yuen, HA ;

Ngai, TJ ;

Louie, SG ;

Yee, KWH ;

Wong, LM ;

Hong, W ;

Lee, LB ;

Town, A ;

Smolich, BD ;

Manning, WC ;

Murray, LJ ;

Heinrich, MC ;

Cherrington, JM .

BLOOD, 2003, 101 (09) :3597-3605

[20] Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma [J].

Papworth, K ;

Grankvist, K ;

Ljungberg, B ;

Rasmuson, T .

TUMOR BIOLOGY, 2005, 26 (04) :201-206

← 1 2 3 →